Scientific
Advisory Board
We are proud of our Scientific Advisory
Board. Our founding Chairman until his death in November 2004 was Sir John Vane, a Nobel Laureate who co-discovered the molecule protacyclin,
upon which much of our business is based. Click here for Martine Rothblatt's tribute to Sir John.
The knowledge
of our Scientific Advisory Board members
is of immense value to us as we explore
the use of prostacyclin-like molecules
(such as Remodulin)
in cardiovascular conditions.
As we extended our business into infectious diseases, we
strengthened our Board with Nobel Laureate Baruch S. Blumberg,
M.D., Ph.D., discovered of the hepatitis B virus, who
succeeded Sir John Vane as Chairman. Dr. Blumberg also created
the hepatitis B vaccine, an innovation that has saved millions
of lives. Professor Blumberg works closely with another of our
board members, Raymond A. Dwek, F.R.S., who discovered our
iminosugar-based anti-infective platform of molecules (such as
our lead drug candidate for treating hepatitis C, UT231B).
Professor Dwek is also able to share with us some of the
brilliance that permeates University of Oxford's Biochemistry
Department, which he chairs, and its Glycobiology Institute,
which he founded. The anti-infectives expertise of professors
Blumberg and Dwek is further complemented on the UT Scientific
Advisory Board by Dr. Urban Ramstedt.
It
is also important to have individuals
on a Scientific Advisory Board who have
operational responsibility and vast
expertise overseeing the appropriateness
of how scientific breakthroughs are
translated into clinical protocols,
and how medical discoveries are integrated
into clinincal practice. For us, we
are honored to have as these individuals: Sir Magdi
Yacoub, M.D., F.A.C.S., one
of the world's foremost transplant surgeons
and cardiopulmonary scientists, and
Victor J. Dzau, M.D., President and CEO, Duke University
Medical Center & Health System, the Hon. Louis W. Sullivan,
M.D., founding President and now President Emeritus of
Morehouse School of Medicine and former Secretary of the
United States Department of Health and Human Services,
and Robert Bourge, MD, head of the world's largest pulmonary
hypertension practice at University of Alabama-Birmingham
Medical Center.
The
Scientific Advisory Board at United
Therapeutics plays an important role.
Fortunately for us, the caliber of the
scientists on our Board are second to
none in our missions of developing prostacyclin-like
molecules and arginine supplementation
for cardiovascular medicine and proving
the usefulness of iminosugar compounds
for safely treating serious infectious
disease.
United Therapeutics
Scientific Advisory Board
Sir
John Vane, D.Sc., F.R.S. (1927-2004), Founding Chairman
Professor
Baruch S. Blumberg, Ph.D., Chairman
Robert C. Bourge, MD
Professor
Raymond A. Dwek, F.R.S.
Professor
Victor J. Dzau, M.D.
Urban
Ramstedt, Ph.D.
Hon.
Louis W. Sullivan, M.D.
Sir
Magdi Yacoub, M.D., F.A.C.S.
